- In June 2025, Vivasure Medical received CE Mark approval in Europe for its PerQseal Elite vascular closure system. This bioresorbable technology represents a significant advancement in post-procedure closure for large-bore arterial access sites. By eliminating permanent implants, the system reduces long-term complications, reinforcing Vivasure's position in the innovative segment of the Endovascular Stent Grafts market
- In June 2025, Nectero Medical was granted two new Category III CPT codes by the American Medical Association for its Endovascular Aneurysm Stabilization Treatment (EAST) system. This minimally invasive platform is designed to reinforce abdominal aortic aneurysms before rupture, improving outcomes in patients not suitable for traditional EVAR. The move signals growing recognition of pre-emptive stent graft strategies in clinical care
- In May 2025, Endospan Ltd. presented promising 30-day results from the TRIOMPHE study for its Nexus aortic arch stent graft system. The data, shared at a major vascular conference, highlighted the device’s safety and effectiveness in managing complex aortic arch pathologies, positioning Endospan at the forefront of next-generation arch repair innovations
- In May 2025, GE HealthCare launched CleaRecon DL, a deep learning-powered CBCT image reconstruction software aimed at enhancing image clarity during endovascular procedures. This tool provides higher-quality imaging with lower radiation doses, enabling more precise placement of stent grafts in complex vascular environments
